Assignee
MEMORIAL SLOAN KETTERING CANCER CENTER
US·413 granted patents·448 pending applications·941 citations·filing 2012–2025
Top patents by PatentIndex Score
861 records- 0197US11000549B2Methods of using chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted May 11, 2021·6 cites·20 claims
- 0297US10906956B2Methods of treatments using chimeric antigen receptors targeting G-protein coupled receptorMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 2, 2021·7 cites·20 claims
- 0397US10821135B2Nucleic acid molecules encoding chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Nov 3, 2020·7 cites·30 claims
- 0496US11810677B2Systems and methods for multiple instance learning for classification and localization in biomedical imagingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Nov 7, 2023·4 cites·20 claims
- 0596US11538155B2Systems and methods for multiple instance learning for classification and localization in biomedical imagingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Dec 27, 2022·8 cites·19 claims
- 0696US11176677B2Deep interactive learning for image segmentation modelsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Nov 16, 2021·5 cites·20 claims
- 0796US10918665B2Chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Feb 16, 2021·16 cites·57 claims
- 0896US10736962B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Aug 11, 2020·15 cites·22 claims
- 0996US10445879B1Systems and methods for multiple instance learning for classification and localization in biomedical imagingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Oct 15, 2019·21 cites·20 claims
- 1096US9540448B2T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2MEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Jan 10, 2017·32 cites·10 claims
- 1195US12036279B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jul 16, 2024·2 cites·8 claims
- 1295US11986503B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted May 21, 2024·2 cites·14 claims
- 1395US11725059B2Antibodies targeting B-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Aug 15, 2023·3 cites·40 claims
- 1495US10963673B2Identifying regions of interest from whole slide imagesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 30, 2021·25 cites·20 claims
- 1594US12056878B2Deep interactive learning for image segmentation modelsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Granted Aug 6, 2024·2 cites·18 claims
- 1694US11682117B2Deep interactive learning for image segmentation modelsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jun 20, 2023·3 cites·20 claims
- 1794US11285209B2Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 29, 2022·3 cites·10 claims
- 1894US11253560B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 22, 2022·3 cites·19 claims
- 1994US10654928B2Compositions and methods for immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted May 19, 2020·12 cites·24 claims
- 2094US10639366B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted May 5, 2020·10 cites·16 claims
- 2194US10562972B2Antibodies targeting B-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Feb 18, 2020·9 cites·67 claims
- 2294US10548930B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·15 cites·18 claims
- 2394US9688772B2Anti-GD2 antibodiesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Jun 27, 2017·8 cites·33 claims
- 2493US11541087B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 3, 2023·2 cites·12 claims
- 2593US10947314B2Antibodies targeting b-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Mar 16, 2021·5 cites·30 claims
- 2693US10810736B2Systems and methods for multiple instance learning for classification and localization in biomedical imagingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Oct 20, 2020·12 cites·20 claims
- 2793US10730941B2Antigen-binding proteins targeting CD56 and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Granted Aug 4, 2020·10 cites·36 claims
- 2893US10548989B2Nanoparticle immunoconjugatesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·7 cites·20 claims
- 2993US10512662B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 24, 2019·6 cites·20 claims
- 3093US10167285B2Small-molecule HSP90 inhibitorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Jan 1, 2019·6 cites·13 claims
- 3193US10117897B2Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Nov 6, 2018·13 cites·26 claims
- 3293US9840533B2Compositions and methods for altering second messenger signalingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2014·Granted Dec 12, 2017·37 cites·44 claims
- 3392US12263220B2Compositions and methods for immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Granted Apr 1, 2025·1 cites·18 claims
- 3492US11242375B2Immune cell compositions and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 8, 2022·5 cites·58 claims
- 3592US11096972B2Seneca Valley Virus (SVV) cellular receptor targeted oncotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Aug 24, 2021·4 cites·15 claims
- 3692US10869868B2Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemiaMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 22, 2020·4 cites·13 claims
- 3792US10370452B2Effective generation of tumor-targeted T cells derived from pluripotent stem cellsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Aug 6, 2019·21 cites·96 claims
- 3892US10316093B2Antibodies, compositions, and usesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Jun 11, 2019·8 cites·26 claims
- 3991US11738058B2Seneca valley virus (SVV) cellular receptor targeted oncotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Aug 29, 2023·2 cites·20 claims
- 4091US11702472B2Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jul 18, 2023·2 cites·31 claims
- 4191US11274116B2Minimal saponin analogues, synthesis and use thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 15, 2022·3 cites·10 claims
- 4291US11267901B2Compositions and methods for immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Mar 8, 2022·12 cites·18 claims
- 4391US11229669B2Cells comprising non-HLA restricted T cell receptorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 25, 2022·3 cites·30 claims
- 4491US10590196B2Antibodies targeting G-protein coupled receptor and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Mar 17, 2020·10 cites·46 claims
- 4591US10287365B2Anti-GD2 antibodiesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted May 14, 2019·5 cites·38 claims
- 4691US10131686B2Compositions and methods for altering second messenger signalingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Nov 20, 2018·12 cites·19 claims
- 4791US10124023B2Compositions and methods for immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Nov 13, 2018·15 cites·15 claims
- 4891US10111963B2Nanoparticle drug conjugatesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Oct 30, 2018·9 cites·34 claims
- 4990US11682186B2Detection of annotated regions of interest in imagesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jun 20, 2023·3 cites·20 claims
- 5090US11369322B2Methods and systems for retrospective internal gatingMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jun 28, 2022·2 cites·20 claims
Showing the top 50 of 861 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MEMORIAL SLOAN KETTERING CANCER CENTER files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →